Very Early-Onset Inflammatory Bowel Disease (VEO-IBD)
- Home
- Solutions
- By Diseases
- Intestinal Diseases
- Very Early-Onset Inflammatory Bowel Disease (VEO-IBD)
Very early onset inflammatory bowel disease (VEO-IBD) is one of the categories of pediatric IBD which is characterized by greater genetic risk, predominant colonic involvement, more extensive and severe inflammation, and a more complex response to therapies. As a specialized service provider, Protheragen focus on providing therapeutic development services for VEO-IBD and other unusual forms of gastrointestinal diseases.
VEO-IBD describes an IBD diagnosis before the age of 6 years. A Canadian population study demonstrated the rate of IBD with childhood-onset had a childhood incidence of 9.68 cases per 100,000 children which has recently increased to a prevalence of 38.25 per 100,000. VEO-IBD accounts for 3%-15% of all pediatric IBD cases. It remains a relatively uncommon form of IBD but appears to be the most rapidly emerging form amongst all individuals with IBD. VEO-IBD also differs from pediatric and adult-onset IBD regarding the type of disease, the site of the lesion, the disease's behaviors, and the heritable factors involved.
Fig.1 Global epidemiology of pediatric-onset IBD. (Kuenzig, M. E., et al., 2022)An increase in VEO-IBD causative monogenic variants has been reported. A significant number of the monogenic etiologies seem to represent primary immune deficiencies (PIDs), which further underscores the unregulated immune aspect of VEO-IBD.
The VEO-IBD monogenic etiologies described so far can be grouped into 6 major types:
Fig.2 Pathways causing enteropathy and autoimmunity. (Nameirakpam, J., et al., 2019)
| Drug Names | Mechanism of Action | Targets | NCT Number | Research Phase |
| Thalidomide | Incorporating immunomodulatory, anti-angiogenic, and TNF blocking capabilities. | TNF | NCT06382519 | N/A |
| Umbilical Cord Blood Transplantation | Repair impaired IL10 signaling. | IL10 | NCT04170192 | N/A |
| Macrophage Transplantation | Restoration of IL10 receptor fault in macrophages. | IL10 | / | Preclinical |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our professionals will work with you and provide strategic consultancy to help refine your research focus. We offer solutions that have a deep understanding of gastrointestinal diseases that can greatly affect the success of your project. A team member is always with you, ensuring that you have the resources and guidance needed to navigate the complexities of diagnostic, therapeutic, and disease model development.
Comprehending VEO-IBD is essential and animal models contribute greatly to this investigation as they provide important details regarding the genetic, immunological, and environmental aspects of VEO-IBD. To develop effective therapies and improve the outcomes of children suffering from VEO-IBD, we will advance customized animal model development services and conduct further research through these models.
The colitis model is produced by chemical injury to the intestinal wall using dextran sulfate sodium (DSS) or trinitrobenzene sulfonic acid (TNBS).
VEO-IBD pathology can be studied with specific animal models that have VEO-IBD-associated gene mutations such as IL10, IL10RA, IL-10RB, or XIAP.
Protheragen's resources include all stages of therapy development: from pharmacology, pharmacokinetics, and drug safety assessment. Together we can change the therapy of VEO-IBD! Check out our portfolio of products and services on our website, or contact our team directly. Take the first step toward discovering new solutions with us.
References
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.